References
- Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guide-lines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267–84.
- Weisfelt M, de Gans J, van de Beek D. Bacterial meningi-tis: a review of effective pharmacotherapy. Expert Opin Phar- macother 2007; 8: 1493–504.
- Dagan R, Velghe L, Rodda JL, Klugman KP. Penetration of meropenem into the cerebrospinal fluid of patients with in-flamed meninges. J Antimicrob Chemother 1994; 34: 175–9.
- Nau R, Lassek C, Kinzig-Schippers M, Thiel A, Prange HW, Sörgel F. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ven-triculostomy. Antimicrob Agents Chemother 1998; 42: 2012–6.
- Nicasio AM, Quintiliani R Jr, DeRyke CA, Kuti JL, Nicolau DP. Treatment of Serratia marcescens meningitis with pro-longed infusion of meropenem. Ann Pharmacother 2007; 41: 1077–81.
- Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic mod-elling and Monte Carlo simulation. J Antimicrob Chemother 2007; 60: 1038–44.
- Craig WA. Pharmacokinetic/pharmacodynamic parame-ters: rationale for antibacterial dosing of mice and men. Clin In-fect Dis 1998; 26: 1–10.
- Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10–22.
- van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Com-munity-acquired bacterial meningitis in adults. N Engl J Med 2006; 354: 44–53.
- Tzanakaki G, Mastrantonio P. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int J Antimicrob Agents 2007; 29: 621–9.
- Santos LC, Simoes J, Severo M, Vazquez J, Lecour H. Bacterial meningitis in an urban area: etiologic study and prog-nostic factors. Infection 2007; 35: 406–13.
- Ikeda K, Ikawa K, Morikawa N, Miki M, Nishimura S, Kobayashi M. High-performance liquid chromatography with ul-traviolet detection for real-time therapeutic drug monitoring of meropenem in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856: 371–5.
- Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A phar- macokinetic analysis program (multi) for microcomputer. J Phar-macobiodyn 1981; 4: 879–85.
- Ikawa K, Morikawa N, Hayato S, Ikeda K, Ohge H, Sueda T. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents 2007; 30: 270–3.
- Ikawa K, Morikawa N, Matsuda S, et al. Peritoneal pene-tration and pharmacodynamic exposure of intravenous cefozo-pran in abdominal surgery patients. Int J Antimicrob Agents 2007; 30: 352–5.
- Yamaguchi K, Murakami M, Takahashi A, et al. Nation-wide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Jpn J Antibiot 2005; 58: 655–89.
- Watanabe Y, Takahashi C, Ohya H, Okazaki N, Onoue Y. Antibiotic susceptibility of Neisseria men ingitidis from healthy and diseased persons in Japan. Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 2007; 81: 669–74.
- Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J An-timicrob Chemother 2005; 55: 601–7.
- Burgess DS, Frei CR, Lewis Ii JS, Fiebelkorn KR, Jor-gensen JH. The contribution of pharmacokinetic-pharmacody-namic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria men ingitidis. Clin Mi-crobiol Infect 2007; 13: 33–9.
- Turner PJ. Use of a program-specific website to dissemi-nate surveillance data obtained from the Meropenem Yearly Sus-ceptibility Test Information Collection (MYSTIC) Study. Diagn Microbiol Infect Dis 2005; 53: 273–9.
- Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic phar-macodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117–27.
- Andes DR, Craig WA. Pharmacokinetics and pharmaco-dynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999; 13: 595–618.